MARKET

WVE

WVE

WAVE LIFE SCIENC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.02
-0.06
-0.99%
After Hours: 6.00 -0.02 -0.33% 17:35 05/10 EDT
OPEN
6.09
PREV CLOSE
6.08
HIGH
6.33
LOW
5.89
VOLUME
1.05M
TURNOVER
--
52 WEEK HIGH
19.98
52 WEEK LOW
4.820
MARKET CAP
300.13M
P/E (TTM)
-1.5121
1D
5D
1M
3M
1Y
5Y
Wave Life Sciences to Present at RBC Capital Markets Global Healthcare Virtual Conference
CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno,...
GlobeNewswire · 3h ago
Spinal Muscular Atrophy Medicine Market Size, Share, Growth,Trends, COVID-19 Analysis and Forecast 2021-2028
pune, India, Fri, 07 May 2021 06:29:14 / Comserve Inc. / -- The global Spinal Muscular Atrophy Medicine market is segmented by company, region (country), by...
Comserve · 3d ago
Wave Life Sciences to Webcast Conference Call of First Quarter 2021 Financial Results on May 13, 2021
GlobeNewswire · 05/03 20:05
Is WVE Stock A Buy or Sell?
Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to ...
Insider Monkey · 04/26 06:39
WAVE Life Sciences Stock Shows Every Sign Of Being Possible Value Trap
GuruFocus News · 04/22 08:12
Global Dystrophin Market Outlook, Industry Analysis and Prospect 2021-2026
Apr 15, 2021 (Heraldkeepers) -- The Dystrophin market report provides a detailed analysis of global market size, regional and country-level market size,...
Heraldkeepers · 04/15 16:07
Global Huntington Disease Protein Market Outlook, Industry Analysis and Prospect 2021-2026
Heraldkeepers · 04/15 15:04
Global Targeted Drug Delivery System Market 2021 Outlook to 2027 Top Companies in Market, Trends & Growth Factors and Details for Business Development
The Express Wire · 04/09 08:56
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of WVE. Analyze the recent business situations of WAVE LIFE SCIENC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average WVE stock price target is 9.14 with a high estimate of 17.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 161
Institutional Holdings: 54.20M
% Owned: 108.72%
Shares Outstanding: 49.86M
TypeInstitutionsShares
Increased
36
4.52M
New
22
988.63K
Decreased
30
4.04M
Sold Out
24
2.50M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.01%
Pharmaceuticals & Medical Research
-0.44%
Key Executives
Chairman/Independent Director
Christian Henry
President/Chief Executive Officer/Director
Paul Bolno
Chief Financial Officer/Chief Accounting Officer
Kyle Moran
Chief Human Resource Officer
Jonathan Rosin
Senior Vice President
Christopher Francis
Senior Vice President
Kenneth Rhodes
Senior Vice President
Chandra Vargeese
Other
Michael Panzara
Director
Gregory Verdine
Independent Director
Mark Corrigan
Independent Director
Peter Kolchinsky
Independent Director
Koji Miura
Independent Director
Adrian Rawcliffe
Independent Director
Ken Takanashi
Independent Director
Heidi Wagner
No Data
About WVE
WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. The nucleic acid therapeutics, which the Company is developing are stereopure. A stereopure oligonucleotide includes molecules with atoms arranged in three-dimensional orientations at each linkage. The Company has three programs in Huntington's disease (HD) and Duchenne Muscular Dystrophy (DMD), and three additional development candidates.

Webull offers kinds of Wave Life Sciences Ltd stock information, including NASDAQ:WVE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, WVE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading WVE stock methods without spending real money on the virtual paper trading platform.